CRISPR-Cas13a system: a novel approach to precision oncology.
作者信息
Zhang Junxia, You Yongping
机构信息
Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 210029, China.
出版信息
Cancer Biol Med. 2020 Feb 15;17(1):6-8. doi: 10.20892/j.issn.2095-3941.2019.0325.
Abstract
摘要
相似文献
1
CRISPR-Cas13a system: a novel approach to precision oncology.
Cancer Biol Med. 2020 Feb 15;17(1):6-8. doi: 10.20892/j.issn.2095-3941.2019.0325.
2
Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
Cancer Treat Res Commun. 2021;27:100289. doi: 10.1016/j.ctarc.2020.100289. Epub 2021 Feb 10.
3
Futuristic approach to cancer treatment.
Gene. 2021 Dec 30;805:145906. doi: 10.1016/j.gene.2021.145906. Epub 2021 Aug 16.
4
CRISPR Advancements for Human Health.
Mo Med. 2024 Mar-Apr;121(2):170-176.
5
Harnessing the evolving CRISPR/Cas9 for precision oncology.
J Transl Med. 2024 Aug 8;22(1):749. doi: 10.1186/s12967-024-05570-4.
6
CRISPR cures and cancer vaccines: researchers can help to shepherd them to market.
Nature. 2024 Jun;630(8016):269. doi: 10.1038/d41586-024-01714-0.
7
A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine.
Clin Transl Med. 2021 Mar;11(3):e355. doi: 10.1002/ctm2.355.
8
Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?
Neurotherapeutics. 2021 Jul;18(3):1515-1523. doi: 10.1007/s13311-021-01081-y. Epub 2021 Jul 7.
9
The New Frontiers in Cancer.
Trends Cancer. 2016 Oct;2(10):533. doi: 10.1016/j.trecan.2016.10.008. Epub 2016 Oct 21.
10
CRISPR cancer trial success paves the way for personalized treatments.
Nature. 2022 Nov;611(7936):433-434. doi: 10.1038/d41586-022-03676-7.
引用本文的文献
1
NLC Delivery of EGFP Plasmid to TM4 Cell Nuclei for Targeted Gene Therapy.
Adv Pharm Bull. 2024 Oct;14(3):613-622. doi: 10.34172/apb.2024.050. Epub 2024 Jun 22.
2
Advances in application of CRISPR-Cas13a system.
Front Cell Infect Microbiol. 2024 Feb 19;14:1291557. doi: 10.3389/fcimb.2024.1291557. eCollection 2024.
3
Advancements in the synergy of isothermal amplification and CRISPR-cas technologies for pathogen detection.
Front Bioeng Biotechnol. 2023 Oct 10;11:1273988. doi: 10.3389/fbioe.2023.1273988. eCollection 2023.
4
Cas13d: A New Molecular Scissor for Transcriptome Engineering.
Front Cell Dev Biol. 2022 Mar 31;10:866800. doi: 10.3389/fcell.2022.866800. eCollection 2022.
5
Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Mol Ther. 2021 Nov 3;29(11):3305-3318. doi: 10.1016/j.ymthe.2021.07.002. Epub 2021 Jul 16.
6
Multifunctional microfluidic chip for cancer diagnosis and treatment.
Nanotheranostics. 2021 Jan 1;5(1):73-89. doi: 10.7150/ntno.49614. eCollection 2021.
7
LncRNAs in Cancer: From garbage to Junk.
Cancers (Basel). 2020 Oct 31;12(11):3220. doi: 10.3390/cancers12113220.
本文引用的文献
1
CRISPR/Cas13a-Powered Electrochemical Microfluidic Biosensor for Nucleic Acid Amplification-Free miRNA Diagnostics.
Adv Mater. 2019 Dec;31(51):e1905311. doi: 10.1002/adma.201905311. Epub 2019 Oct 30.
2
The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells.
Adv Sci (Weinh). 2019 Aug 29;6(20):1901299. doi: 10.1002/advs.201901299. eCollection 2019 Oct 16.
3
Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma.
Adv Sci (Weinh). 2019 Jul 24;6(17):1900782. doi: 10.1002/advs.201900782. eCollection 2019 Sep 4.
4
A Synthetic Light-switchable System based on CRISPR Cas13a Regulates the Expression of LncRNA MALAT1 and Affects the Malignant Phenotype of Bladder Cancer Cells.
Int J Biol Sci. 2019 Jun 4;15(8):1630-1636. doi: 10.7150/ijbs.33772. eCollection 2019.
5
Adeno-associated virus vector as a platform for gene therapy delivery.
Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9.
6
Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo.
Adv Sci (Weinh). 2018 Oct 25;6(1):1801423. doi: 10.1002/advs.201801423. eCollection 2019 Jan 9.
7
A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Cancer Lett. 2018 Sep 1;431:171-181. doi: 10.1016/j.canlet.2018.05.042. Epub 2018 Jun 2.
8
Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
Mol Cell. 2018 Apr 19;70(2):327-339.e5. doi: 10.1016/j.molcel.2018.02.028. Epub 2018 Mar 15.
9
Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6.
Science. 2018 Apr 27;360(6387):439-444. doi: 10.1126/science.aaq0179. Epub 2018 Feb 15.
10
RNA virus interference via CRISPR/Cas13a system in plants.
Genome Biol. 2018 Jan 4;19(1):1. doi: 10.1186/s13059-017-1381-1.
Zotero 插件